Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects
Despite the great success in the diagnosis and treatment of immuno-inflammatory rheumatic diseases (IIRD), which led to a significant improvement in the prognosis in many patients, the fundamental medical problems of this pathology – the restoration of quality of life and reduction of mortality to t...
Saved in:
| Main Authors: | E. L. Nasonov, A. M. Lila |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2019-03-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/2668 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
EFFICACY AND SAFETY OF TOFACITINIB FOR IMMUNEMEDIATED INFLAMMATORY RHEUMATIC DISEASES (PART II)
by: E. L. Nasonov, et al.
Published: (2020-04-01) -
Efficacy and safety of tofacitinib for immune-mediated inflammatory rheumatic diseases (Part I)
by: E. L. Nasonov, et al.
Published: (2020-02-01) -
Relationship between systemic inflammatory response and hypercoagulation in patients with immuno-inflammatory rheumatic diseases
by: Yu. A. Zhuravleva, et al.
Published: (2023-06-01) -
Janus kinase inhibitors in immunoinflammatory diseases: 10 years of clinical practice in rheumatology
by: E. L. Nasonov, et al.
Published: (2022-05-01) -
Janus kinase inhibitors in the treatment of psoriatic arthritis
by: E. Yu. Loginova, et al.
Published: (2022-02-01)